NEL-ASA
13.7.2022 21:36:12 CEST | Business Wire | Press release
Nel Hydrogen US, a subsidiary of Nel ASA (Nel, OSE:NEL), has received a purchase order from Viva Energy Australia Pty. Ltd. (Viva Energy) for a MC500 containerized PEM water electrolyser. When installed, the electrolyser will be the biggest in Australia and provide green hydrogen to a fleet of heavy fuel cell vehicles.
Viva Energy is an ASX listed company that owns the Geelong refinery and supplies a service station network of around 1,350 Shell and Liberty service stations across Australia. Viva Energy also supplies fuels and other products to a range of commercial customers.
As part of its Geelong Energy Hub, Viva Energy is building a new energy service station near its Geelong refinery that will provide battery charging and hydrogen refueling. The system delivered by Nel is a containerized solution with a production capacity up to 1,063kg/day, and will supply fuel cell grade hydrogen directly on site to the dedicated fueling station. The project received a grant from the Australian Renewable Energy Agency (ARENA) as part of ARENA's Advancing Renewables Program and the Victorian Government also contributed to the project via the Renewable Hydrogen Commercialization Pathways Fund.
“It is a great pleasure to collaborate with Viva Energy and our local partner ENGV to develop this unique flagship project in Australia. This project is an important milestone for Australia’s targeted efforts to decarbonize the mobility sector and create a local hydrogen economy”, says Raymond Schmid, VP Sales and Marketing EMEA and Oceania.
The contract has an approximate value of about EUR 4m, and the system is expected to be delivered in Q3 2023.
About Nel ASA | www.nelhydrogen.com
Nel is a global, dedicated hydrogen company, delivering optimal solutions to produce, store, and distribute hydrogen from renewable energy. We serve industries, energy, and gas companies with leading hydrogen technology. Our roots date back to 1927, and since then, we have had a proud history of development and continuous improvement of hydrogen technologies. Today, our solutions cover the entire value chain: from hydrogen production technologies to hydrogen fueling stations, enabling industries to transition to green hydrogen, and providing fuel cell electric vehicles with the same fast fueling and long range as fossil-fueled vehicles - without the emissions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220713005826/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TVS Motor Company Returns to EICMA With New Models for Europe26.10.2026 12:45:00 CET | Press release
A year after its Milan debut, TVS Motor returns with a rapidly expanding European footprint and Italian sales up 110%Peyman Kargar to lead TVS Motor’s next phase of global growth as the company expands European footprint TVS Motor Company (TVSM), a global leader in two- and three-wheeler manufacturing, returns to EICMA in Milan this November, one year after its debut at the world’s largest two-wheeler exhibition. The company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET. The TVS stand is in Hall 18, Stand I64. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026990290/en/ TVS Motor Company will present new models for Europe at a press conference on Tuesday, 3 November at 10:00 CET at EICMA this year. EICMA 2025 marked the beginning of TVS Motor's European growth journey. Since then, the company has focused on establishing the foundations for long-term success, building its deal
Two-Year Data of Pimicotinib Demonstrated Durable Tumor Control and Sustained Improvement in TGCT Symptoms and Joint Function26.10.2026 12:00:00 CET | Press release
Improvements in symptoms of pain, stiffness, and range of motion were sustained through two yearsTumor responses remained robust1 and durable2Not intended for U.K.-, U.S.- or Canada-based media Merck, a leading science and technology company, today announced new two-year follow-up results from the Phase 3 MANEUVER study evaluating pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The study showed that among patients initially randomized to pimicotinib, improvements in symptoms and joint function were observed as early as Week 5, sustained through two years, and continued to improve over time. Tumor responses remained robust1 and durable,2 and the safety profile was consistent with previous analyses. The findings are being presented today in the Sarcoma poster session at the European Society for Medical Oncology (ESMO) Congress 2026 (Presentation # 3747P). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022
WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN26.10.2026 11:30:00 CET | Press release
Second limited-edition WHOOP x SR_A collection brings “performance for life” to new WHOOP bands, technical apparel, outerwear, and accessories designed for movement across city and rural environments. WHOOP, the human performance brand, today announced Layer 2 of PROJECT TERRAIN, its multiyear collaboration with British designer Samuel Ross MBE and his design atelier, SR_A. Building on the sold out debut collection launched in March 2026, Layer 2 expands PROJECT TERRAIN to its next season connecting lifestyle and performance for movement, adaptability and zone based training. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261026029587/en/ WHOOP and Samuel Ross MBE Unveil Layer 2 of PROJECT TERRAIN While the first PROJECT TERRAIN collection harnessed dense cities and modern training grounds, Layer 2 explores performance through material, silhouette and tactility. Drawing on the textures, conditions, and flux of the natural wo
Bleeding gums? Don't ignore the warning signs – the first stage of gum disease can be reversed26.10.2026 11:28:00 CET | Press release
Oral-B iO helps you avoid new tooth and gum issues—and if you have existing gum problems, it can resolve them quicker than a manual toothbrush. Gums bleeding when brushing can happen to any of us, and it is easy to ignore. But blood in the sink is a sign that something is not right with your mouth. Bleeding gums often indicate gingivitis, the earliest and most common form of gum disease. The good news: gingivitis can be reversed with proper oral hygiene. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022835650/en/ Oral-B iO Left untreated, gingivitis can progress into periodontitis, a more severe stage of gum disease that can only be managed, not reversed, and can lead to losing teeth over time. Healthy gums matter beyond the mouth, too. Oral health and systemic health are deeply interconnected, with inflammation and bacteria from oral diseases contributing to conditions such as heart disease, diabetes and dementia. "Gums
Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 202626.10.2026 08:00:00 CET | Press release
Clinical and preclinical presentations reflect the company’s ongoing exploration of peripheral neuropathic pain Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in peripheral neuropathic pain (PNP) at the International Association for the Study of Pain (IASP) 2026 World Congress in Bangkok, Thailand, taking place from 26 to 30 October. The research spans new Phase 2 findings on incobotulinumtoxinA in postherpetic neuralgia (PHN) and post-surgical/post-traumatic neuropathic pain (PS/PTNP), as well as preclinical studies exploring potential biological mechanisms involved in effects of incobotulinumtoxinA on PNP models, highlighting Merz Therapeutics’ growing presence in neuropathic pain. In the PHN population of the Phase 2 PaiNT trial, results over 20 weeks favored incobotulinumtoxinA versus placebo treatment. In an exploratory analysis of average daily pain (ADP) intensity, the greates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom